Hong Kong Respiratory Medicine

B Taylor Thompson. The Lancet, Early Online Publication, 12 December 2011doi:10.1016/S0140-6736(11)61845
 
In The Lancet , Fang Gao Smith and the BALTI-2 study investigators 1 report the findings of their phase-3 randomised trial of intravenous salbutamol for acute respiratory distress syndrome (ARDS). The trial, based on reliable preclinical evidence and an encouraging phase-2 trial, was stopped early because of safety concerns.

β-agonists had been an appealing therapeutic option for ARDS in view of extensive clinical experience, low cost, and an excellent safety profile when used for patients with obst ...

Weblink here